We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FRTA
2551
DELISTED
Forterra, Inc
FRTA
| $326K | ﹤0.01% |
28,209
+1,796
| +7% | +$17.5K |
|
|
STR
2552
DELISTED
Sitio Royalties
STR
| $324K | ﹤0.01% |
11,487
+142
| +1% | +$3.62K |
|
2553
Turning Point Brands
TPB
$1.62B
| $324K | ﹤0.01% |
11,329
+151
| +1% | +$3.79K |
|
2554
Accuray
ARAY
$33.9M
| $323K | ﹤0.01% |
114,662
+467
| +0.4% | +$1.3K |
|
2555
Quanterix
QTRX
$173M
| $323K | ﹤0.01% |
13,679
+958
| +8% | +$21.9K |
|
2556
Investar Holding Corp
ISTR
$418M
| $322K | ﹤0.01% |
13,413
-35
| -0.3% | -$861 |
|
2557
Apyx Medical
APYX
$176M
| $321K | ﹤0.01% |
37,912
+566
| +2% | +$4.09K |
|
2558
PCB Bancorp
PCB
$394M
| $321K | ﹤0.01% |
18,568
+29
| +0.2% | +$487 |
|
|
MRLN
2559
DELISTED
Marlin Business Services Corp
MRLN
| $321K | ﹤0.01% |
14,609
-32
| -0.2% | -$726 |
|
2560
Merchants Bancorp
MBIN
$2.55B
| $320K | ﹤0.01% |
24,317
-859
| -3% | -$10K |
|
2561
Crinetics Pharmaceuticals
CRNX
$8.9B
| $319K | ﹤0.01% |
12,698
+72
| +0.6% | +$1.37K |
|
2562
LSB Industries
LXU
$707M
| $318K | ﹤0.01% |
98,409
+6,996
| +8% | +$23.6K |
|
2563
Orrstown Financial Services
ORRF
$851M
| $318K | ﹤0.01% |
14,045
+33
| +0.2% | +$726 |
|
|
AVID
2564
DELISTED
Avid Technology Inc
AVID
| $317K | ﹤0.01% |
36,958
+203
| +0.6% | +$1.5K |
|
|
ECOM
2565
DELISTED
CHANNELADVISOR CORPORATION
ECOM
| $317K | ﹤0.01% |
35,085
+748
| +2% | +$6.86K |
|
|
CSTR
2566
DELISTED
CapStar Financial Holdings, Inc
CSTR
| $316K | ﹤0.01% |
18,976
+142
| +0.8% | +$2.37K |
|
2567
Rocky Brands
RCKY
$374M
| $315K | ﹤0.01% |
10,707
+32
| +0.3% | +$944 |
|
|
CNCE
2568
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $315K | ﹤0.01% |
34,194
+210
| +0.6% | +$1.49K |
|
|
TBIO
2569
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $314K | ﹤0.01% |
38,522
+1,413
| +4% | +$13K |
|
|
BREW
2570
DELISTED
Craft Brew Alliance, Inc.
BREW
| $314K | ﹤0.01% |
19,060
+275
| +1% | +$3.43K |
|
2571
Oil-Dri
ODC
$1.41B
| $313K | ﹤0.01% |
17,278
+36
| +0.2% | +$632 |
|
|
HABT
2572
DELISTED
The Habit Restaurants, Inc. - Class A
HABT
| $312K | ﹤0.01% |
29,942
-1
| -0% | -$10 |
|
2573
Flexsteel Industries
FLXS
$325M
| $311K | ﹤0.01% |
15,609
+240
| +2% | +$4.19K |
|
|
GTYH
2574
DELISTED
GTY Technology Holdings, Inc. Common Stock
GTYH
| $311K | ﹤0.01% |
52,760
+11,242
| +27% | +$60.7K |
|
|
XOG
2575
DELISTED
Extraction Oil & Gas, Inc. Common Stock
XOG
| $309K | ﹤0.01% |
145,931
-672
| -0.5% | -$1.37K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.